Aktienanalyse zu Corvus Pharmaceuticals Inc (CRVS)CRVSCorvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corvus Pharmaceuticals is not a good buy right now due to its current price of $10.52, which is significantly below the analyst target of $40, but the low RSI of 31.317 indicates oversold conditions. However, the recent negative earnings reports and high volatility present risks.

6 analysts cover CRVS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 13.33.